Short Shots is a collection of technically vulnerable charts culled from the Negative Inflecting and Toppy columns within our Weekly Compass report or from various technical screening processes. The charts contained in this report have developed concerning technical patterns that suggest further price deterioration is likely. For these reasons Short Shots can also be a great source of ideas for investors interested in short-selling candidates.
A director at Johnson & Johnson bought 1,250 shares at 206.150USD and the significance rating of the trade was 82/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years cle...
A director at Medtronic Plc sold 30,000 shares at 101.948USD and the significance rating of the trade was 80/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly ...
Moody's Ratings (Moody's) assigned a Baa3 rating to the proposed new senior unsecured notes issuance of Baxter International Inc. (Baxter). At the same time, we assigned a (P)Baa3 rating to Baxter's senior unsecured shelf registration. There are no changes to Baxter's existing ratings including the ...
Coasting as We Stalk for Buying Opportunity; Downgrading Discretionary to Underweight We had been near-term bullish on the S&P 500 (SPX) since our 4/22/25 Compass, however, we are officially downgrading our near-term outlook to neutral. The SPX, Nasdaq 100 (QQQ), and Russell 2000 (IWM) are breaking below their 50-day MAs and are also violating their multi-month uptrends, signaling a consolidation period is here. With that said, our intermediate-term outlook remains bullish (as of our 5/14/25 Co...
Moody's Ratings (Moody's) downgraded the ratings of Baxter International Inc. (Baxter) including the senior unsecured ratings to Baa3 from Baa2 and the commercial paper rating to Prime-3 from Prime-2. The outlook is stable. Previously, the ratings were on review for downgrade. This action concludes ...
A director at Boston Scientific Corp sold 12,891 shares at 98.284USD and the significance rating of the trade was 78/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years ...
Moody's Ratings (Moody's) placed the ratings of Baxter International Inc. (Baxter) on review for downgrade. The ratings placed on review include the Baa2 senior unsecured ratings and Prime-2 commercial paper rating. Previously, the outlook was negative. The review is prompted by operating pressure...
Moody's Ratings (Moody's) said that on 14 October, Johnson & Johnson ("J&J") announced that it intends to separate its Orthopaedics business into an independent company called DePuy Synthes. The separation of the Orthopaedics business, which is part of J&J's medical devices segment ("MedTech") will ...
A director at Abbott Laboratories sold 5,550 shares at 134.551USD and the significance rating of the trade was 69/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years cle...
Moody's Ratings (Moody's) affirmed Baxter International Inc.'s (Baxter) ratings, including its Baa2 senior unsecured ratings and Prime-2 commercial paper rating. At the same time, we revised the outlook to negative from stable. The ratings affirmation considers Baxter's good scale and diversity as...
Moody's Ratings (Moody's) has completed a periodic review of the ratings of Baxter International Inc. and other ratings that are associated with this issuer. The review was conducted through a rating committee held on 17 June 2025 in which we reassessed the appropriateness of the ratings in the con...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.